Biotech heavyweight Biogen (NASDAQ: BIIB)has now lost over 13% of its value so far this year. To be fair, this year hasn't been kind to biotechs in general, thanks to President Trump's aggressive trade policies with China. But Biogen's value has been declining at a far faster rate than the industry as a whole due to stiffer competition in the all-important multiple sclerosis (MS) space.
Is Biogen Inc. a Buy?
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться